BIOFIL CHEM & PHARMA LTD Intrinsic Value
BIOFILCHEM · Healthcare · Current price ₹32.05
Is BIOFIL CHEM & PHARMA LTD undervalued?
DocStoX estimates the fair value of BIOFIL CHEM & PHARMA LTD at ₹25 per share, versus the current market price of ₹32. That puts the stock about -23.1% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹12), Relative P/E (₹52), Graham floor (₹21). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹12 (bear) to ₹25 (base) to ₹52 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹32 versus an intrinsic value of ₹25, BIOFIL CHEM & PHARMA LTD currently offers -23.1% of negative margin (i.e. a premium).
More on BIOFIL CHEM & PHARMA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.